Mr Lu, the founder of Biosensors International Group Ltd, was our chairman and CEO from 2001 to 2008. He has retained his leadership position as chairman of the Group since January 2008.
Mr Lu has more than 30 years’ experience in the medical industry. As chairman, Mr Lu’s experience, leadership and track record has proven to be critical. While serving as CEO, he was responsible for our business strategies and directions, the implementation of our corporate plans and policies, and the general management of our business.
Prior to founding Biosensors, Mr. Lu established Asia-based operations for the Medical Division of Gould Inc., specializing in surgical and critical care catheters and instruments. He held various senior positions with Gould before advancing to the position of president of the Asia-Pacific division. In 1986, Mr. Lu participated in a management-led leveraged buyout of the division from Gould. A year later, the newly spun-off Spectramed Inc was listed on the NASDAQ, until it was sold to British Oxygen Corporation in 1988. Mr Lu then served as president-Asia Pacific with British Oxygen until 1990. In 1990, Mr. Lu also founded Sun Instruments-Japan, Sunscope International in California and Biosensors International in Singapore, all of which are now subsidiaries of Biosensors International Group Ltd.
Mr. Lu holds a Bachelor of Science degree in Engineering from the University of California at Berkeley and a Masters degree in Business Administration from the Thunderbird Graduate School of International Management in Arizona.
Mr Jose Calle Gordo joined Biosensors on 1 September 2014 as the Chief Executive Officer. He had a successful career with over 25 years of broad business and management experience in the medical devices industry, having served in various vice president and managerial roles at Abbott, Guidant and Eli Lilly. He led the global team that developed and commercialized Xience, a family of drug eluting stents (DES) and market leader for the treatment of coronary artery disease while serving as Vice President and General Manager of Drug Eluting Stents, Vascular Intervention at Guidant based in Santa Clara, California (US).
As Vice President of Abbott Vascular based in Brussels, he later managed the international operations of Abbott Vascular outside of the US and more recently he led globally the commercial introduction of bioresorbable vascular scaffolds (ABSORB BVS) and MitraClip, the world's first percutaneous mitral valve repair therapy.
During his earlier years with Guidant and Eli Lilly, he contributed in different managerial roles to the commercial and therapy development of the implanted defibrillator and cardiac resynchronization therapy.
Mr. Calle Gordo received his Biomedical/Medical Engineering (Electrical Engineering) degree from Universidad Politecnica de Madrid, Spain.
Mr. Jiang joined the Biosensors board as a non-executive, non-independent director on 3 October 2011. On 29 January 2014, Mr. Jiang was appointed as an Executive Director and as Biosensors’ Chief Operating Officer.
Mr. Jiang was a former consultant of Shandong Weigao Group Medical Polymer Company Limited ("Shandong Weigao"). Prior to this, he served as the head of corporate strategy and the deputy general manager of Shandong Weigao from June 2002 until August 2011.
Mr. Jiang obtained a Masters degree in Accounting from Northeast University of Finance and Economics in the People’s Republic of China in 1998. Mr. Jiang has an extensive experience in accounting and financial management.
Dr. Wang joined Biosensors in 2001 and has been involved in our product development and operating activities since then, first serving as our vice president, research & development, then as chief operating officer, as well as president and chief executive officer of JW Medical Systems Ltd, before becoming co-CEO then CEO of Biosensors. In May 2014 Dr. Wang assumed the role of Chief Technology Officer.
Prior to joining Biosensors in 2001, Dr. Wang was manager of new product development for Johnson & Johnson (Cordis) and project group leader in stent delivery systems for Guidant Corporation. Dr. Wang has been granted more than 20 U.S. and European patents in medical devices and technology and has published more than 30 scientific papers on polymer materials and processing.
Dr. Wang received his Doctorate degree in polymer science from Case Western Reserve University, Cleveland, Masters degree in Science in Chemical Engineering from Clarkson University, Potsdam and Bachelor of Science degree in Chemistry and Chemical Engineering from Tsinghua University, Beijing.
Mr. Jump has over 30 years’ experience in the medical device industry. He joined Biosensors in 2003 as president of our subsidiary Occam International B.V. in The Netherlands and soon afterwards became the managing director of Biosensors Europe SA. In 2005 he was additionally appointed senior vice president – sales and marketing, with responsibility for sales, sales support and global marketing for Europe, Middle East, Africa, India, North and South America. In 2007 he was also given global responsibility for clinical and regulatory activities. In July 2010, Mr. Jump became our president and chief executive officer, a position he held until March 2012, when he was appointed President of Biosensors’ newly-created Cardiovascular Business Unit.
Prior to joining Biosensors, Mr. Jump served as CEO of Xitact Medical Simulation, which was acquired by Mentice. He has served as a board member with several medical device companies, and is currently on the board of BeneChill Inc, PneumRx Inc and Veryan Medical. He has also served on the senior management team of several medical device companies, including Embol-X Inc., Alliance Medical Technologies, Cardio Thoracic Systems (CTS), Haemonetics S.A. and Pfizer Hospital Products Group. Mr. Jump received his Bachelor of Science degree from Indiana University, a graduate degree in Management Research from the University of South Australia and a Masters degree (MSc) from London Business School.
Mr. Ede joined Biosensors in April 2011.
Prior to joining Biosensors, he worked for Mindray Medical International, the largest medical equipment company in China, which trades on the New York Stock Exchange. He has served on Mindray’s board of directors since 2006, later becoming chief financial officer, where he led the integration of Mindray’s acquisition projects in the United States. Mr. Ede stepped down as Mindray’s CFO on joining Biosensors but remains as a independent board member.
Prior to his service at Mindray, he was CFO for the Asia Pacific region of JDSU Corporation, a NASDAQ-listed company which is one of the largest global providers of optical components and testing solutions for telecommunications companies.
Mr. Ede started his career in commercial banking with Bank of Hawaii and later as a financial analyst with Hewlett Packard, before joining ATL Ultrasound as finance manager. Following a promotion to director of finance-international by ATL, he was appointed managing director for the Asian region of SonoSite, a spin-off company from ATL Ultrasound. He has also acted as a consultant to a variety of organizations on their Asia-based operations.
Mr. Ede received a Bachelor of Business Administration degree from University of Hawaii and a MBA degree from the University of Washington.